GRI Bio Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference

Core Insights - GRI Bio, Inc. is a biotechnology company focused on developing Natural Killer T (NKT) cell modulators for treating inflammatory, fibrotic, and autoimmune diseases [1][3] - The company’s lead program, GRI-0621, is an oral therapeutic aimed at treating idiopathic pulmonary fibrosis, addressing a significant unmet medical need [3] - GRI Bio is also developing a pipeline of novel type 2 diverse NKT (dNKT) agonists for systemic lupus erythematosus, supported by a library of over 500 proprietary compounds [3] Company Overview - GRI Bio is a clinical-stage biopharmaceutical company aiming to change the treatment landscape for inflammatory, fibrotic, and autoimmune diseases [3] - The company’s therapies target NKT cells, which play a crucial role in the inflammatory response and disease progression [3] - The company’s focus on NKT cells positions it uniquely in the biopharmaceutical industry, linking innate and adaptive immune responses [3] Leadership Insights - Dr. Marc Hertz, the President and CEO, shared his dedication to the company and insights into its development programs during a recent investor conference [2]